ClinicalTrials.gg
CompletedNCT00280696Updated Feb 11, 2015

A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures

A Phase 3 interventional study of Levetiracetam 250 mg and Levetiracetam 500 mg in Epilepsies, Partial, sponsored by UCB Japan Co. Ltd.. Completed at 37 sites in Japan. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-02-11.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
4th of 18
352 · median 173
Started
2005
the only one that year
Phase 3
10 of 18
none open now
Registered
10th of 18
by date
Lead sponsor
2 of 18
UCB Japan Co. Ltd.

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 4th largest by enrollment, is the only one that started in 2005, is one of 10 in phase 3, and was the 10th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

A double-blind, randomized, multicenter, placebo controlled 5 parallel groups, confirmatory trial to evaluated the efficacy and safety of levetiracetam used as adjunctive treatment in patients from 16 to 65 years with epilepsy suffering from partial onset seizures.

03

Conditions studied

  • Epilepsies, Partial

Browse trials for

Keywords

  • Epilepsies, Partial,
  • Keppra, levetiracetam
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Epileptic patients who fulfill the following criteria are eligible for inclusion in the study:

  • Subjects aged from 16 to 65 years at the acquisition of to the trial participation
  • Seizure type: subjects with epileptic seizures which were diagnosed as partial seizures more than 2 years ago according to "Clinical and electroencephalographic classification of epileptic seizures (1981)" defined by the International League Against Epilepsy (ILAE) and confirmed with an EEG that has been performed within 1 year before Screening or at the Screening Visit
  • Subjects whose previous therapy before screening involved at least two standard anti-epileptic drugs (AEDs) for partial seizures, and in whom it can be confirmed that the doses met the daily dose specified for the treatment of epilepsy in the package insert and that the therapy has been continued for at least 3 months
  • Frequency of epileptic seizures: subjects experiencing partial seizures at least 12 times in 12 weeks during the Baseline Period (Week -12 to Week 0) and at least twice in every 4 weeks

Exclusion criteria

Exclusion Criteria:

The following patients are not eligible for inclusion into the study:

  • Subjects who were diagnosed with status epilepticus within 3 months before screening
  • Subjects with no partial seizures of which frequency was measured during the Baseline Period
  • Subjects who underwent surgery for epilepsy within 2 years before Screening or who were scheduled to undergo brain surgery during the study period and within 4 weeks after the completion of this study
  • Subjects with a history of oral treatment with Levetiracetam (LEV)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
352 participants (actual)

Study arms

  • Experimental
    Lev 0.5 g

    Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).

    Drug: Levetiracetam 250 mg

  • Experimental
    Lev 1 g

    Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).

    Drug: Levetiracetam 250 mg · Drug: Levetiracetam 500 mg

  • Experimental
    Lev 2 g

    Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).

    Drug: Levetiracetam 250 mg · Drug: Levetiracetam 500 mg

  • Experimental
    Lev 3 g

    Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).

    Drug: Levetiracetam 250 mg · Drug: Levetiracetam 500 mg

  • Placebo comparator
    Placebo

    Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).

    Other: Placebo

Interventions

  • * Active Substance: Levetiracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 250 mg * Route of Administration: Oral Use

    Also known as: Keppra

  • * Active Substance: Levetiracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 500 mg * Route of Administration: Oral Use

    Also known as: Keppra

  • OtherPlacebo

    * Active Substance: Placebo * Pharmaceutical Form: Film-coated tablet * Concentration: 250 mg and 500 mg * Route of Administration: Oral Use

06

What researchers measure

Primary outcomes

  1. Percent reduction from Baseline in partial (Type I) seizure frequency per week over the Evaluation Period

    Time frame: From Baseline to the 12-week Evaluation Period

Secondary outcomes

  1. Partial (Type I) seizure frequency per week over the Evaluation Period

    Time frame: 12-week Evaluation Period

  2. Partial (Type I) seizure responder rates (50 %, 75 %) over the Evaluation Period

    Time frame: From Baseline to the 12-week Evaluation Period

  3. Seizure freedom over the Evaluation Period

    Time frame: 12-week Evaluation Period

  4. Categorized percentage reduction from Baseline in partial (Type I) seizure frequency per week over the Evaluation Period

    Time frame: From Baseline to the 12-week Evaluation Period

  5. Percentage reduction from Baseline in seizure frequency per week by seizure subtype (IA, IB, IC, IA + IB, other) over the Evaluation Period

    Time frame: From Baseline to the 12-week Evaluation Period

07

Study locations

37 sites
  • Aichi-gun, Aichi, Japan
  • Nagoya, Aichi, Japan
  • Nayoga, Aichi, Japan
  • Hirosaki, Aomori, Japan
  • Kitakyusyu, Fukuoka, Japan
  • Kurume, Fukuoka, Japan
  • Fukuyama, Hiroshima, Japan
  • Asahikawa, Hokkaido, Japan
  • Hakodate, Hokkaido, Japan
  • Sapporo, Hokkaido, Japan
  • Kobe, Hyogo, Japan
  • Kahoku-gun, Ishikawa, Japan
  • Kikuchi-gun, Kumamoto, Japan
  • Sendai, Miyagi, Japan
  • Omura, Nagasaki, Japan
  • Izumi, Osaka, Japan
  • Neyagawa, Osaka, Japan
  • Suita, Osaka, Japan
  • Kawachi-gun, Tochigi, Japan
  • Kodaira, Tokyo, Japan
  • Ube, Yamaguchi, Japan
  • Chiba, Japan
  • Fukuoka, Japan
  • Gihu, Japan
  • Hiroshima, Japan
  • Kagoshima, Japan
  • Kobe, Japan
  • Kyoto, Japan
  • Miyazaki, Japan
  • Nagaoka, Japan
  • Niigata, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Shizuoka, Japan
  • Tokyo, Japan
  • Toyama, Japan
  • Yamagata, Japan
08

References and documents

Publications

  • Inoue Y, Yagi K, Ikeda A, Sasagawa M, Ishida S, Suzuki A, Yoshida K; Japan Levetiracetam N01221 Study Group. Efficacy and tolerability of levetiracetam as adjunctive therapy in Japanese patients with uncontrolled partial-onset seizures. Psychiatry Clin Neurosci. 2015 Oct;69(10):640-8. doi: 10.1111/pcn.12300. Epub 2015 May 13. PubMed 25854635 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2006
First posted
Jan 23, 2006
Start
Nov 2005
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Last update
Feb 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00280696
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Jan 23, 2006
Start date
Nov 2005
Primary completion
Nov 2007
Completion
Nov 2007
Last update
Feb 11, 2015

Study contacts

UCB Clinical Trial Call Center
study director · UCB Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion